| Document |
Document Title |
|
WO/2021/062559A1 |
This disclosure relates to carmabinoid derivatives of Formula (1) wherein R4 or R7 is a carboxamide group, pharmaceutical compositions comprising these compounds and methods of using the carmabinoid derivatives. These compounds are poten...
|
|
WO/2021/066608A1 |
The present invention relates to a compound for inducing the expression of the anti-aging gene klotho and a production method therefor. The compound represented by chemical formula 1, according to the present invention, has an excellent ...
|
|
WO/2021/060277A1 |
Provided are, inter alia, compounds useful as aminating agents capable of introducing an amino group protected by a deprotectable protecting group into a wide range of substates under relatively moderate conditions, an aminating agent ha...
|
|
WO/2021/058970A1 |
A method of identifying a first object, the method comprises: providing a first object comprising a material, the material comprising a polymer and a luminescent compound; and detecting an absorption and/or excitation and/or emission spe...
|
|
WO/2021/057852A1 |
The present invention relates to the field of agricultural protection. Disclosed are an oxazoline compound, a synthesis method therefor and an application thereof. The oxazoline compound has a structure represented by formula (I), wherei...
|
|
WO/2021/055627A1 |
The invention provides substituted N-heterocyclic carboxamides and related compounds, compositions containing such compounds, medical kits, and methods for using such compounds and compositions to treat a medical disorder, e.g., cancer, ...
|
|
WO/2021/037022A1 |
Disclosed is a method for preparing 4-methyl-5-alkoxy oxazole, which belongs to the field of chemical synthesis. The method comprises subjecting a N-formylalaninate ester to a cyclization reaction to obtain the 4-methyl-5-alkoxy oxazole....
|
|
WO/2021/032857A1 |
The invention provides the imidazole, oxazole and thiazole compounds and use thereof in methods for treating a disease or a disorder, such as infectious diseases and cancer, wherein inhibition of sphingosine-1-phosphate lyase is benefici...
|
|
WO/2021/033504A1 |
A method for producing a carbonyl compound by means of a flow reaction, wherein: a triphosgene solution is introduced into a flow path (I); the triphosgene solution comes into contact with a solid catalyst, which is affixed to at least a...
|
|
WO/2021/033505A1 |
A method for producing a carbonyl compound by means of a flow reaction, wherein: a triphosgene solution, a tertiary amine solution and an active hydrogen-containing compound solution are introduced into different flow paths and are cause...
|
|
WO/2021/031533A1 |
Disclosed in the present invention is a method for synthesizing N-substituted phenyl-5-hydroxymethyl-2-oxazolidinone, wherein the synthesis method involves: 3-R 2-4-R 1-phenylamine and epoxy chloropropane being used as raw materials to c...
|
|
WO/2020/247819A3 |
Described herein is a compound of Formula I or a pharmaceutically acceptable salt thereof: wherein Ring A R1, R2, a, b, and n are as defined herein. Also described is a method of treating a subject having a disorder in need of treatment,...
|
|
WO/2021/032209A1 |
Provided are a compound of formula (I-a), an isomer thereof or a pharmaceutically acceptable salt thereof as a Hemagglutinin inhibitor, and a preparation method thereof. The compound is useful for preparing a medicament for treating a di...
|
|
WO/2021/028512A1 |
The present invention provides new arylsulfonamide compounds having the general formula (I), wherein L, R1, R2, R3 and R4are as described herein, compositions including the compounds, processes of manufacturing the compounds and methods ...
|
|
WO/2021/029146A1 |
Provided are: a polymerizable composition including a compound indicated by general formula (I–1) or general formula (I–2) and a polymerizable compound; an application therefor; a compound indicated by general formula (II); and an ap...
|
|
WO/2021/026257A1 |
Described herein are compounds and pharmaceutical compositions containing such compounds which are prodrugs of ALOX-15 inhibitors. Also described herein are methods for using such compounds in the treatment of disease.
|
|
WO/2021/026179A1 |
The present invention is directed to compounds of the formula (I) wherein all substituents are defined herein, as well as pharmaceutically acceptable compositions comprising compounds of the invention and methods of using said compositio...
|
|
WO/2021/018834A1 |
The present invention relates to compounds of Formula (I), wherein R1, R2, R3, R4x, R4y, m, n and G are as defined herein. The invention further relates to herbicidal compositions which comprise a compound of Formula (I), to their use fo...
|
|
WO/2021/018833A1 |
The present invention relates to compounds of Formula (I), wherein R1, R2, R3, R4x, R4y, k and G are as defined herein. The invention further relates to herbicidal compositions which comprise a compound of Formula (I), to their use for c...
|
|
WO/2021/007663A1 |
This disclosure relates to cannabinoid derivatives of formula (I), pharmaceutical compositions comprising them, and methods of using the cannabinoid derivatives in treating or preventing a diseases associated with a cannabinoid receptor ...
|
|
WO/2021/001858A1 |
The present invention relates to process for the preparation of 2-(3,5-dichlorophenyl)-1,3-benzoxazole-6-carboxylic acid of formula (I), its pharmaceutically acceptable salts and polymorphs thereof which are used in the treatment of card...
|
|
WO/2020/263484A1 |
This document relates to methods and materials for treating a neuromyelitis optica (NMO) spectrum disorder such as NMO. For example, one or more tetracycline antibiotics can be administered to a mammal having, or at risk of developing, a...
|
|
WO/2020/264499A1 |
The present invention provides compounds, compositions thereof, and methods of using the same. The compounds include an IRAK binding moiety capable of binding to IRAK4 and a degradation inducing moiety (DIM). The DIM could be DTM a ligas...
|
|
WO/2020/257043A1 |
The embodiments of present invention provide processes and intermediates for the preparation of D1 PAM I: Formula (I).
|
|
WO/2020/250223A1 |
The invention relates to a novel substituted amino acids, agricultural compositions comprising the novel substituted amino acids, and their use for controlling undesired plant growth alone or in combination with crop protection agents su...
|
|
WO/2020/249957A1 |
Compounds of general formula (I) and their tautomeric forms all enantiomers and isotopic variants and salts and solvates thereof: Formula (I), wherein (AA) represents a single or a double bond and R1, R2, X1, X2, X3, X4, X5, Y and Z are ...
|
|
WO/2020/247819A2 |
Described herein is a compound of Formula I or a pharmaceutically acceptable salt thereof: wherein Ring A R1, R2, a, b, and n are as defined herein. Also described is a method of treating a subject having a disorder in need of treatment,...
|
|
WO/2020/242277A1 |
The present invention relates to a pharmaceutical composition for the prevention or treatment of inflammatory diseases, comprising: a naphthoquinone or benzoindazole compound which increases the ratio of NAD+ and NAD+/NADH through activi...
|
|
WO/2020/238559A1 |
Disclosed are a de-C2-symmetric diphenylamine-type chiral bisoxazoline ligand as shown in formula 3, a synthesis method therefor and the use thereof in an asymmetric catalytic reaction. The C2-symmetry of the ligand is removed by introdu...
|
|
WO/2020/232852A1 |
Disclosed in the present invention are an organic light-emitting material and a preparation method therefor, and an organic light-emitting device. The organic light-emitting material comprises a benzophenanthrene derivative which has goo...
|
|
WO/2020/232655A1 |
Presented is an organic electroluminescent compound and an organic electroluminescent device comprising the same. By comprising the organic electroluminescent compound of the present disclosure, it is possible to provide an organic elect...
|
|
WO/2020/232325A1 |
The present disclosure relates to solid state forms of Tafamidis and salts thereof, processes for preparation thereof and pharmaceutical compositions thereof.
|
|
WO/2020/230134A1 |
The present invention relates to novel ACSS2 inhibitors having activity as anti-cancer therapy, treatment of alcoholism, and viral infection (e.g., CMV), composition and methods of preparation thereof, and uses thereof for treating viral...
|
|
WO/2020/225569A1 |
The present invention relates to a compound of formula (I), or a pharmaceutically acceptable salt or hydrate thereof, wherein: the group X-Y is -NHSO2- or -SO2NH-; Z is a monocyclic aryl or heteroaryl group, each of which is optionally s...
|
|
WO/2020/222118A1 |
Non-aromatic fluoroalkenyl heterocyclic compounds having general formula (I), agronomic compositions containing said compounds having formula (I) and their use for the control of nematodes in agricultural crops, are described.
|
|
WO/2020/216298A1 |
Disclosed are a compound as shown in formula I, a stereoisomer thereof, and a pharmaceutically acceptable salt thereof. The present invention also relates to a pharmaceutical composition containing the compound of formula I and use of th...
|
|
WO/2020/207753A1 |
The present invention relates to an improved process for the preparation of 1-deoxy-1-methylamino-D- glucitol 2-(3,5-dichlorophenyl)-6-benzoxazolecarboxylate, also known as tafamidis meglumine. The process of the present invention is par...
|
|
WO/2020/206367A1 |
Disclosed are methods for preparing deuterated analogs of D-serine and compounds useful for preparing deuterated analogs of D-serine.
|
|
WO/2020/204864A1 |
The present invention relates to novel benzoxazole derivative compounds with anticancer effects and the use of these compounds in the treatment of various cancer types. In the present invention, anticarcinogenic compounds are obtained by...
|
|
WO/2020/205470A1 |
The present disclosure provides compounds and methods for inhibiting or degrading the N-terminal domain of the androgen receptor, as well as methods for treating cancers such as prostate cancer.
|
|
WO/2020/198368A1 |
The present disclosure relates to compounds, pharmaceutical compositions comprising such compounds, and use of such compounds in methods of treatment or in medicaments for treatment of inflammatory diseases and certain neurological disor...
|
|
WO/2020/198247A1 |
The present invention provides a process of using an alloy nanoparticle catalyst to catalyze one pot chemical reactions for synthesizing functional polymers with controlled polymerization and properties. In particular, the present invent...
|
|
WO/2020/195588A1 |
Provided are an actinic-light-sensitive or radiation-sensitive resin composition that has high resolution ability and is capable of preventing device contamination, as well as an actinic-light-sensitive or radiation-sensitive film, patte...
|
|
WO/2020/186202A1 |
The present disclosure compounds of the formula (I-A) or (I), wherein the variables are defined herein, as well as pharmaceutical compositions thereof. The present disclosure also provides methods for the use of said compounds and/or pha...
|
|
WO/2020/171221A1 |
The purpose of the present invention is to provide an organic EL element in which a capping layer is combined with various materials of the element so that properties of each of the materials of the element can be effectively demonstrate...
|
|
WO/2020/169971A1 |
A solidification or crystallisation method is disclosed providing at least a first organic compound, providing at least one volatile co-former organic compound, forming a mixture of at least the first organic compound and the co-former o...
|
|
WO/2020/172609A1 |
The present invention provides novel compounds with increased plasma stability that modulate PAR1 signaling, and methods of using them. The present invention provides methods of using the novel PAR1 modulators for the treatment of a numb...
|
|
WO/2020/166630A1 |
The purpose of the present invention is: to provide an organic compound for use as a material for a highly efficient and durable organic EL device, the organic compound having excellent electron injection/transport performance, having a ...
|
|
WO/2020/167831A1 |
The present disclosure provides methods of preparing a compound of Formula (1): wherein R1, R2, and R3 are as defined as set forth in the application. In one embodiment, a compound of Formula (1) is prepared in >95% chemical purity and >...
|
|
WO/2020/157069A1 |
The present disclosure relates to compounds of Formula (I): and to their pharmaceutically acceptable salts, pharmaceutical compositions, methods of use, and methods for their preparation. The compounds disclosed herein are useful for inh...
|
